The marine alkaloid naamidine A promotes caspase-dependent apoptosis in tumor cells

Anti-Cancer Drugs

Volumn 20, Issue 6, 2009, Pages 425-436

  LaBarbera, Daniel V ^a,c,e   Modzelewska, Katarzyna ^a,c   Glazar, Amanda I ^e   Gray, Phillip D ^b,c,d   Kaur, Manjinder ^e   Liu, Tong ^c   Grossman, Douglas ^b,c   Harper, Mary Kay ^a   Kuwada, Scott K ^b,c,d   Moghal, Nadeem ^b,c,f,g   Ireland, Chris M ^a  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Antitumor agent; Apoptosis; Caspase; Marine natural products; Mitochondria

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ALKALOID; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE 8; CASPASE 9; DEATH RECEPTOR; EPIDERMAL GROWTH FACTOR; FAS ANTIGEN; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NAAMIDINE A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL DEATH; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME DEGRADATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL CULTURE; TUMOR XENOGRAFT;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL CULTURE TECHNIQUES; CELL CYCLE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMIDAZOLES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PORIFERA; TREATMENT OUTCOME;

EID: 67249152374     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32832ae55f     Document Type: Article

References (42)

1. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005; 5:876-885. (Pubitemid 41746032)
2. Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov 2002; 1:111-121.
3. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008; 13:472-482. (Pubitemid 351766797)
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70. (Pubitemid 30046295)
5. Catassi A, Cesario A, Arzani D, Menichini P, Alama A, Bruzzo C, et al. Characterization of apoptosis induced by marine natural products in non small cell lung cancer A549 cells. Cell Mol Life Sci 2006; 63:2377-2386. (Pubitemid 44653047)
6. Nagle DG, Zhou YD, Mora FD, Mohammed KA, Kim YP. Mechanism targeted discovery of antitumor marine natural products. Curr Med Chem 2004; 11:1725-1756. (Pubitemid 38821341)
7. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003; 66:1022-1037.
8. Newman DJ. Natural products as leads to potential drugs: an old process or the new hope for drug discovery? J Med Chem 2008; 51:2589-2599. (Pubitemid 351620778)
9. Butler MS. Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep 2008; 25:475-516. (Pubitemid 351725315)
10. Newman DJ, Cragg GM. Natural products from marine invertebrates and microbes as modulators of antitumor targets. Curr Drug Targets 2006; 7:279-304. (Pubitemid 43744847)
11. Simmons TL, Andrianasolo E, McPhail K, Flatt P, Gerwick WH. Marine natural products as anticancer drugs. Mol Cancer Ther 2005; 4:333-342. (Pubitemid 40340212)
12. Carmely S, Ilan M, Kashman Y. 2-amino imidazole alkaloids from the marine sponge Leucetta chagosensis. Tetrahedron 1989; 45:2193-2200.
13. Copp BR, Fairchild CR, Cornell L, Casazza AM, Robinson S, Ireland CM. Naamidine A is an antagonist of the epidermal growth factor receptor and an in vivo active antitumor agent. J Med Chem 1998; 41:3909-3911. (Pubitemid 28447318)
14. James RD, Jones DA, Aalbersberg W, Ireland CM. Naamidine A intensifies the phosphotransferase activity of extracellular signal-regulated kinases causing A-431 cells to arrest in G1. Mol Cancer Ther 2003; 2:747-751.
15. Pumiglia KM, Decker SJ. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc Natl Acad Sci U S A 1997; 94:448-452. (Pubitemid 27053653)
16. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol 1997; 17:5598-5611. (Pubitemid 27357656)
17. Cotter MA, Thomas J, Cassidy P, Robinette K, Jenkins N, Florell SR, et al. N-acetylcysteine protects melanocytes against oxidative stress/damage and delays onset of ultraviolet-induced melanoma in mice. Clin Cancer Res 2007; 13:5952-5958. (Pubitemid 47583923)
18. Jones RG, Li X, Gray PD, Kuang J, Clayton F, Samowitz WS, et al. Conditional deletion of betal integrins in the intestinal epithelium causes a loss of Hedgehog expression, intestinal hyperplasia, and early postnatal lethality. J Cell Biol 2006; 175:505-514. (Pubitemid 44708073)
19. Hacker G. The morphology of apoptosis. Cell Tissue Res 2000; 301:5-17. (Pubitemid 30459851)
20. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, et al. Features of apoptotic cells measured by flow cytometry. Cytometry 1992; 13:795-808.
21. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995; 184:39-51.
22. Johannessen LE, Knardal SL, Madshus IH. Epidermal growth factor increases the level of the cyclin-dependent kinase (CDK) inhibitor p21/CIP1 (CDK-interacting protein 1) in A431 cells by increasing the half-lives of the p21/CIP1 transcript and the p21/CIP1 protein. Biochem J 1999; 337 (Pt 3):599-606. (Pubitemid 129511003)
23. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281:1305-1308. (Pubitemid 28406815)
24. Dong C, Li Q, Lyu SC, Krensty AM, Clayberger C. A novel apoptosis pathway activated by the carboxyl terminus of p21. Blood 2005; 105:1187-1194. (Pubitemid 40170892)
25. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281:1309-1312.
26. Belizario JE, Alves J, Occhiucci JM, Garay-Malpartida M, Sesso A. A mechanistic view of mitochondrial death decision pores. Braz J Med Biol Res 2007; 40:1011-1024. (Pubitemid 47232855)
27. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 1998; 60:619-642. (Pubitemid 28157889)
28. Chaoui D, Faussat AM, Majdak P, Tang R, Perrot JY, Pasco S, et al. JC-1, a sensitive probe for a simultaneous detection of P-glycoprotein activity and apoptosis in leukemic cells. Cytometry B Clin Cytom 2006; 70:189-196.
29. Smiley ST, Reers M, Mottola-Hartshorn C, Lin M, Chen A, Smith TW, et al. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci USA 1991; 88:3671-3675. (Pubitemid 21916685)
30. Mohan S, Dhanalakshmi S, Mallikarjuna GU, Singh RP, Agarwal R. Silibinin modulates UVB-induced apoptosis via mitochondrial proteins, caspases activation, and mitogen-activated protein kinase signaling in human epidermoid carcinoma A431 cells. Biochem Biophys Res Commun 2004; 320:183-189. (Pubitemid 38781800)
31. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 2002; 9:459-470. (Pubitemid 34273778)
32. McGinnis KM, Gnegy ME, Park YH, Mukerjee N, Wang KK. Procaspase-3 and poly(ADP)ribose polymerase (PARP) are calpain substrates. Biochem Biophys Res Commun 1999; 263:94-99. (Pubitemid 29443645)
33. Schon M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger J, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95:1138-1149. (Pubitemid 37045392)
34. Boatright KM, Salvesen GS. Mechanisms of caspase activation. Curr Opin Cell Biol 2003; 15:725-731. (Pubitemid 37492933)
35. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-310.
36. Walker DR, Bond JP, Tarone RE, Harris CC, Makalowski W, Boguski MS, et al. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features. Oncogene 1999; 18:211-218. (Pubitemid 29060595)
37. Kwok TT, Mok CH, Menton-Brennan L. Up-regulation of a mutant form of p53 by doxorubicin in human squamous carcinoma cells. Cancer Res 1994; 54:2834-2836. (Pubitemid 24187756)
38. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139. (Pubitemid 38637993)
39. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500. (Pubitemid 38720929)
40. Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, et al. Prospective phase 11 study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006; 24:3340-3346. (Pubitemid 46638887)
41. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005; 353:133-144. (Pubitemid 41058345)
42. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008; 14:2895-2899.